Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.19.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
COSTS AND EXPENSES:        
Research and development $ 1,809,547 $ 1,723,087 $ 4,117,944 $ 3,802,955
General and administrative 1,390,812 1,181,832 2,712,227 2,555,491
Total costs and expenses 3,200,359 2,904,919 6,830,171 6,358,446
LOSS FROM OPERATIONS (3,200,359) (2,904,919) (6,830,171) (6,358,446)
OTHER INCOME:        
Gain/(Loss) on revaluation of derivative warrants 1,000 (20,000) (3,000) (46,950)
Interest income, net 11,798 4,228 23,969 8,882
Total other income (expense), net 12,798 (15,772) 20,969 (38,068)
NET LOSS $ (3,187,561) $ (2,920,691) $ (6,809,202) $ (6,396,514)
BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE $ (0.46) $ (1.69) $ (1.15) $ (3.75)
SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE 6,963,301 1,731,561 5,935,111 1,706,278